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Melanoma follow-up programmes in our department include
clinical investigation and ultrasound B-scans of regional lymph
node basins at 3-month intervals for all patients with high risk
primary tumours. If subcutaneous (s.c.) lesions or suspicious
lymph nodes are detected, fine-needle aspirates are obtained for
cytological examination (FNAC) (Perry et al, 1988; Fornage and
Lorigan, 1989; Schoengen et al, 1993; Basler et al, 1997). Routine
use of FNAC allows definite diagnosis of melanoma metastases
within less than 1 day, it speeds up the organization of necessary
staging procedures, spares the patient from diagnostic surgery and
therefore is also a cost-decreasing approach. However, in necrotic
or small lesions with diameters less than 10 mm, FNAC frequently
reaches its technical limits, especially in those cases, when fine-
needle aspiration comprises less than 100 cells for each smear.
Detection of tyrosinase-RNA, a tissue-specific enzyme regulating
melanin biosynthesis (Kwon et al, 1987; Ponnazhagen et al, 1994),
by use of reverse transcription (RT) and polymerase chain reaction
(PCR) was originally described for melanoma cells circulating in
peripheral blood (Smith et al, 1991). The use of the tyrosinase-RT-
PCR method was later transferred to detect occult melanoma
micrometastases in lymph nodes (Wang et al, 1994; Schwürzer-
Voit et al, 1996; van-der-Verde et al, 1996) and also in the s.c. fat
tissue adjacent to primary melanomas (Proebstle et al, 1996).
The aim of the present study was to evaluate the sensitivity of
the tyrosinase RT-PCR in fine-needle aspirates (FNA-PCR) in
conjunction with ultrasound B-scan and FNAC examination with
particular regard to putative metastases of small size with diame-
ters less than 10 mm.
MATERIALS AND METHODS
Patients
Study patients were recruited from our clinical follow-up
programme for melanoma patients. Sixty-nine patients who had
presented before without regional disease developed 81 new
regional lesions which were worked up by the use of different
diagnostic tools as described in the paper. The outcome of diag-
nostic procedures showed that of these 69 patients 34 had a
regional recurrence of melanoma, 24 of whom were in clinical
stage III and ten in stage IV (AJCC). Additionally, 33 disease-free
melanoma patients and two stage IV patients did not have a
regional lymph node recurrence. Concomitantly, 15 patients with
non-melanoma disease underwent the same diagnostic programme
for control purposes (Table 1).
Patients were seen for clinical follow-up at 3-monthly intervals.
All patients received a thoroughly performed inspection and
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Summary Physical examination and ultrasound B-scan screening are important follow-up procedures in melanoma patients with regional
disease. However, they do not allow definite diagnosis of suspicious lesions. Fine-needle aspiration cytology (FNAC) enhances the diagnostic
accuracy in such patients but, unfortunately, reaches its technical limits, particularly when very small or necrotic lesions are examined. We
therefore tested whether tyrosinase reverse transcription polymerase chain reaction (RT-PCR) of fine-needle aspirates (FNA-PCR) could help
to increase diagnostic sensitivity. With clinical follow-up in 69 melanoma patients 81 regional lymph nodes were detected by ultrasound B-
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obtain RNA at detectable levels in two lymph nodes of two patients. Of 79 lesions which have been completely evaluated by B-scan, FNAC
and FNA-PCR, 44 proved to be melanoma metastases by histopathology, while the remaining 35 lesions were finally classified as
non-specific lymph nodes. Of the 44 melanoma metastases 80% (n = 35) have been detected by B-scan, 90% (n = 39) by FNAC and 100%
(n = 44) by FNA-PCR (P < 0.05 vs FNAC, P < 0.005 vs B-scan). In the subclass of lesions with diameters below 10 mm the sensitivities were
72% (n = 13), 78% (n = 14) and 100% (n = 18) respectively. In 35 regional lymph nodes classified as benign lesions, FNAC was always
negative while FNA-PCR produced one positive result. Neither of these methods did produce false positive results in 15 control lymph nodes
of non-melanoma patients. We conclude, that FNA-PCR might have superior sensitivity as compared to FNAC or ultrasound B-scan,
particularly in melanoma lesions with diameters below 10 mm.
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physical examination of the former site of the primary tumour, the
regional lymph node basins, the in-transit distance as well as a
control of the whole integument. The study was reviewed and
approved by the local ethical committee and written consent was
obtained from all patients.
Ultrasound B-scan
An ultrasound (US) B-scan with a 7.5 MHz linear scanner
(Sonoline, Siemens, Munich, Germany) was used throughout the
study. Sonographic criteria of lymph nodes and metastatic tumours
were applied as listed in Table 2 to reduce operator dependent
interpretation to a minimum. Figure 1 illustrates an example for a
non-specific lymph node with regular architecture and typical
echo-pattern (Figure 1A) and an example for a regional lymph
node metastasis (Figure 1B).
FNAC
Fine needle aspiration biopsies were performed as described
(Schoengen et al, 1993). To ensure appropriate tissue sampling the
aspiration procedure was guided by ultrasound B-scan to control
the precise location of the needle tip. Incidental aspiration of
tissue is avoided by applying suction exclusively at the site
of interest. The aspirate was then spread on a glass slide and
stained by May–Grünwald–Giemsa to allow cytological analysis
(Figure 2).
Tyrosinase FNA-PCR
About 0.3 ml of aspirate were immediately shock-frozen in liquid
nitrogen and stored at –80°C for subsequent molecular biological
evaluation. Total RNA was extracted from the mini-cell-pellet by
means of Rneasy TM total RNA kit® (Qiagen, Hilden, Germany).
RNA is extracted from homogenized cell material via binding to a
silica gel membrane. All precaution was taken to ensure integrity
and purity of RNA. RNA was quantified by UV spectrophotom-
etry at 260 nm and 280 nm and stored at –80°C. A total of 1.5 mg
of total RNA was transcribed by means of 50 ng random hexa-
mers, 10 mM dNTP-mix and 200 units of superscript II RT (Gibco,
BRL, Grand Island, NY, USA). First the mixture was incubated for
50 min at 42°C, then heated up to 70°C to stop RT. After cooling
on ice 2 U ml–1 Escherichia coli RNAase H (Gibco BRL) was
added at a temperature of 37°C. Twenty minutes later the obtained
cDNA was stored at –20°C for subsequent investigation. cDNA of
the SK-mel-28 melanoma cell line (American Type Culture
Collection) served as positive control. Primers for a tyrosinase
PCR designed as a nested PCR were used as described (Smith
et al, 1991). The outer primers HTYR 1 (TTGGCAGATTGT-
CTGTAGCC) and HTYR 2 (AGGCATTGTGCATGCTGCTT)
Table 1 Patients’ characteristics
Melanoma patients Non-melanoma patients
Metastatic Disease-free Other Benign
malignanciesa diagnosis
Number 34 35 9 6
Female sex 53% 66% 67% 100%
Age, median 52 52 72 39
(range) (24–87) (25–83) (67–86) (18–56)
aDiagnoses were non-Hodgkin’s lymphoma (n = 6), malignant fibrous
histiocytoma (n = 1), malignant schwannoma (n = 1) and thyroid carcinoma
(n = 1).
Table 2 Morphological criteria for evaluation of lymph nodes and melanoma
metastases by ultrasound B-scan
Non-specific lymph node Central ultrasound reflexes, reflex-free
margin, ellipsoid shape
No clear diagnosis Uncertain reflex pattern, uncertain shape,
possible diameter below 5 mm
Melanoma metastasis Whole lesion reflex-free, spherical or
balloon-like shape
SIEMENS SI-400 UNI KLINIK ULM MAN   67 Mo 08/05/95
* 10:35:56
ABD
HAUTKLI.
R Ratio
P Protocol
+D= 12mm
¸D=5.3mm
xD= 12mm
D=5.6mm
SIEMENS SI-400 UNI KLINIK ULM MAN   67 Mo12/06/95
* 08:28:35
ABD
HAUTKLI.
R Ratio
P Protocol
+D=8.6mm
¸D=9.6mm
xD=9.6mm
D=9.1mm
Figure 1 (A) Cross-sections of a non-specific lymph node. Ultrasound B-scan shows an ellipsoid lesion with central reflexes and a reflex-free margin in the left
groin of a 37-year-old patient with stage IV melanoma. FNA-PCR and FNAC were negative. (B) Ultrasound B-scan cross-section showing a balloon-shaped,
reflex-free tumour in the right groin of a 34-year-old patient with a primary melanoma originally located at her right lower leg. FNAC, FNA-PCR and
histopathology revealed a melanoma metastasisamplify a product of 284 base pairs, while the inner primers
HTYR 3 (GTCTTTATGCAATGGAACGC) and HTYR 4
(GCTATCCCAGTAAGTGGACT) amplify a product of 207 base
pairs. Two microlitres of cDNA from lymph node aspirates, blood
samples of 1 ml of cDNA of SK-mel 28 melanoma cells were
added to 45 ml PCR starting mixture. Each sample was overlaid
with two drops of mineral oil to prevent evaporation. First delay: 3
min at 94°C, then first hold at 80°C and addition of 1 unit Taq
DNA polymerase (Gibco BRL). Thirty cycles were performed,
each consisting of 45 s at 94°C, 45 s at 60°C and 45 s at 72°C. Last
delay: 5 min at 72°C and finally at 30°C. Five microlitres of the
first PCR-product diluted 1:100 were used for the nested PCR. The
nested PCR was carried out in the same way as the first PCR. To
avoid contamination the reaction mixtures were performed in a
fume hood. Ten microlitres of the second amplified product were
analysed on a 3% agarose gel followed by ethidiumbromide
staining (ca. 80 min, 80 V). One hundred base pair ladder (Gibco
BRL) was used as standard. PCR samples free of cDNA served as
negative controls, PCR samples with cDNA of SK-mel-28
melanoma cell line served as positive control. SK-mel-28 cells
were cultured in RPMI-1640 with 10% heat inactivated fetal calf
serum (Gibco BRL) plus penicillin, streptomycin, 1% L-glutamine
and 1% non-essential amino acids. Negative and positive controls
are run on each agarose gel in addition to patients’ samples. To
ensure that RNA in the tyrosinase gene negative samples has not
been degraded, a parallel PCR run for the detection of glyceralde-
hyde 3-phosphatase dehydrogenase (GAPDH) (housekeeping
enzyme) was performed. The specificity of PCR-products was
examined by sequencing. cDNA was amplified by using HTYR
3/4 with previously marked universal primers M13 (forward and
reverse). Sequencing was performed via dye primer sequencing
(Perkin-Elmer). The analysis of each specimen was carried out on
a 373 DNA sequencer (ABI, Applied Biosystems).
Tyrosinase RT-PCR from peripheral blood
Blood samples from patients were taken at the same time as fine-
needle aspiration biopsies were performed. For RNA preparation,
5 ml EDTA blood were treated with erythrocyte lysis buffer.
Extraction of total RNA was performed by means of Qia shredder
columns and Rneasy TM total RNA kit® (Qiagen GMBH, Hilden,
Germany). A total of 1.5 mg of RNA were used for synthesis of
cDNA. Each PCR course was controlled by a second run starting
from RNA preparation to cDNA synthesis and PCR procedure to
confirm results. PCR from RNA as template, i.e. PCR without RT
was carried out to exclude amplification of genomic cDNA, which
would lead to false-positive results. Processing blood shortly after
collection was regarded as being of great importance.
Tenfold serial dilutions of SK-mel 28 melanoma cells in periph-
eral blood from a healthy donor were performed. One SK-mel-28
melanoma cell in a background of 106 peripheral blood mononu-
clear cells could be detected (Figure 3).
Statistics
McNemar’s test was used to detect significant differences in the
sensitivity of diagnostic procedures. P-values were given one-
sided throughout the paper.
RESULTS
Eighty-one regional lesions were detected with routine clinical
follow-up in 69 patients with malignant melanoma by ultrasound
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Figure 2 FNAC of a melanoma metastasis presenting with large,
dissociated, well conserved pleomorphic cells with large nuclei, high nucleus
plasma relation, atypical mitoses and megacaryotypic cells. Epithelial-cell-
like type of melanoma cells. May–Grünwald–Giemsa-stain
A B C D E F G H I J
Figure 3 Detection of tyrosinase-specific RNA in a sensitivity assay. Five
millilitres of blood of healthy donors was mixed with 1 up to 106 SK-mel-28
cells. Lane A, J: 100 bp ladder; lanes B–G: serial dilutions with 1, 10, 102,
103, 104, 105 and 106 cells; lane H: negative control; lane I: positive controlTyrosinase RT-PCR from fine-needle aspirates 1675
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B-scan examination, nine lesions appeared to be palpable. At the
same visit, FNAC and tyrosinase FNA-PCR examination were
performed, but inadequate handling caused loss of RNA in two
samples of two patients. Therefore, material obtained from 79
lesions of 67 patients was left for comparison of sensitivities.
Forty-four lesions were histopathologically proved to be regional
melanoma metastases of 34 patients (Table 1). Another 35 disease-
free melanoma patients had 35 non-specific regional lymph nodes
as shown by repeated control with clinical follow-up.
Furthermore, 15 lymph nodes of 15 non-melanoma patients were
examined in the same fashion.
Melanoma metastases
Before surgical removal for histopathological examination, 44
regional or in-transit melanoma metastases derived from 34
patients had been simultaneously examined by ultrasound B-scan,
FNAC and by FNA-PCR (Table 3). Only 20% of these lesions
(n = 9, P < 0.0001) had been detected as palpable tumours by
physical examination, whereas 80% of these tumours (n = 35,
P < 0.005) were classified as melanoma metastases by ultrasound
B-scan. Furthermore, 89% (n = 39, P < 0.05) of these metastases
were diagnosed by FNAC and, finally, tyrosinase FNA-PCR was
able to recognize all malignant lesions (n = 44). The P-values
indicate significantly reduced sensitivities for all other methods if
compared to FNA-PCR.
In the subclass of lesions with diameters less than 10 mm, only
one lesion (6%, P < 0.0001) was palpable, ultrasound was able
to detect 72% (n = 13, P < 0.05), FNAC diagnosed 78% (n = 14,
P < 0.07), whereas FNA-PCR again identified 100% (n = 18) of
the suspicious lesions as melanoma metastases. Among lesions
larger than 10 mm in diameter, physical examination detected 31%
(n = 8, P < 0.0001), ultrasound B-scan 85% (n = 22, P < 0.07),
FNAC 96% (n = 25, P = 0.5) and FNA-PCR again 100% of the
melanoma metastases.
Regional lymph nodes of disease-free melanoma and
non-melanoma patients
Thirty-five non-specific regional lymph nodes of disease-free
melanoma patients, nine lymph nodes of patients with other malig-
nancies and six lymph nodes of patients with benign diagnoses
were investigated in the same way as described above for
melanoma metastases (Table 1). A typical lymph node architecture
as confirmed by ultrasound B-scan was necessary to be included in
this group. FNAC revealed negative results in each of these lymph
nodes. Likewise, FNA-PCR was clearly negative in all non-
melanoma patients. However, one lymph node of a disease-free
melanoma patient was positive by RT-PCR but did not relapse
until now during a 24-month period. The RT-PCR for tyrosinase in
the peripheral blood of this patient was negative at the time of
FNA-PCR.
The median follow-up period in the group of disease-free
melanoma patients was at the time of writing this paper 31.5
months (range 9–39 months) (Table 4). Until now, only four
relapses have been observed in this group, all in patients with clin-
ical stages II and III (AJCC). However, only one of these relapses
originated in a lymph node basin which was examined before by
ultrasound B-scan, FNAC or RT-PCR. The interval between study
examination and melanoma relapse was 15 months in this case.
Tyrosinase RT-PCR from peripheral blood
In addition, we performed tyrosinase-RT-PCR from peripheral
blood of melanoma patients and of patients with non-melanoma
disease. RT-PCR from blood of non-melanoma patients was exclu-
sively negative. Table 5 shows the PCR results for all melanoma
patients, from whom a peripheral blood sample was obtained at
Table 3 Histopathologically proven regional melanoma metastasis which
had been investigated before by ultrasound B-scan, FNAC and FNA-PCR
Tumours < 10 mm Tumours > 10 mm Total
(12 patients) (22 patients) (34 patients)
Physical n = 1 n = 8 n = 9
examination (6%) (31%) (20%)
P < 0.0001 P < 0.0001 P < 0.0001
Ultrasound n = 13 n = 22 n = 35
B-scan (72%) (85%) (80%)
P < 0.05 P < 0.07 P < 0.005
FNAC n = 14 n = 25 n = 39
(78%) (96%) (89%)
P < 0.07 P = 0.5 P < 0.05
Diagnosed by n = 18 n = 26 n = 44
FNA-PCR (100%) (100%) (100%)
Total number n = 18 n = 26 n = 44
of tumours (100%) (100%) (100%)
examined
P-values are given in comparison to the FNA-PCR result of the same column.
The number n denotes the number of lesions.
Table 4 Number of relapses and time interval to relapse of disease-free
melanoma patients, calculated from the time of their FNAC and FNA-PCR
investigation of regional lymph nodes
Clinical stage I II III IV Total
(AJCC)
Number of patients 18 10 5 2 35
Number of relapses 0 2 2 NA 4
Intervals to relapse – 14, 15a 10, 12 NA –
(months)
Interval of follow-up 30 29.5 34 NA 31.5
since FNAC in months (15–39) (9–32) (27–39) (9–39)
as median (range)
aNA = not applicable, because of lack of disease-free interval in stage IV
patients. Relapse at the site tested by FNAC and FNA-PCR 15 months later.
Table 5 Percentage of melanoma patients with positive tyrosinase RT-PCR
from peripheral blood at time of fine-needle aspiration procedure
Clinical stage I II III IV All stages
(AJCC)
Positive patients – – 47% 70% 55%
with metastatic (9/19) (7/10) (16/29)
disease
Positive patients 0% 20% 40% 100% 17%
with disease-free (0/18) (2/10) (2/5) (2/2) (6/35)
melanoma
All melanoma 0% 20% 46% 75% 34%
patients (0/18) (2/10) (11/24) (9/12) (22/64)
Total numbers are given in brackets.1676 C Voit et al
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time of fine-needle aspiration. Patients who presented with
melanoma metastases were positive for tyrosinase RT-PCR from
peripheral blood in 47% in clinical stage III, and in 70% in stage
IV disease respectively. Disease-free melanoma patients who
underwent fine-needle aspiration from non-specific lymph nodes
exhibited also a stage dependency of positive PCR results when
peripheral blood was tested. Examining blood samples, tyrosinase
transcripts were detected in none of 18 patients in clinical stage I;
however, in two out of ten patients in stage II, in two out of five in
stage III and in two out of two patients in stage IV.
DISCUSSION
Physical examination at short time intervals is the basis in follow-
up regimens of high risk melanoma patients. Despite a lack of
definitive criteria, during the past decade ultrasound B-scan
examination of soft tissues has become an additional powerful
tool, particularly for detection of subcutaneous in transit lesions
and regional lymph node metastases. Meanwhile, in our depart-
ment, only 20% of lymph node metastases in melanoma patients
are diagnosed by physical examination, whereas 80% are identi-
fied by ultrasound B-scan (Table 3). Routine evaluation of these
lesions by FNAC has accelerated and simplified the planning of
both, staging procedures and therapeutic measures. Diagnostic
surgery, therefore, has become an extraordinarily rare event.
Unfortunately, the successful use of FNAC needs to meet two
major criteria. It first has to be performed by well-trained experts
and, second, the risk of producing low quality smears with low cell
numbers is increased in the case of smaller lesions. Until now,
most studies focusing on the FNAC technique reported exceed-
ingly high rates for sensitivity and specificity (Perry et al, 1988;
Fornage and Lorigan, 1989; Schoengen et al, 1993; Basler et al,
1997), yet were based on results obtained from aspirates of larger
tumours and, originated from clinical centres where experts inves-
tigate large numbers of FNAC samples each year. One aim of this
study was to find out whether the FNA-PCR method could repro-
duce these results. This would be important, because RT-PCR
analysis can be performed by technical assistance staff at low cost
once a PCR laboratory is established.
Since detection of circulating melanoma cells using an RT-PCR
method for identification of tyrosinase transcripts in peripheral
blood (Smith et al, 1991), despite the extraordinary capability to
detect one melanoma cell in 10 ml of blood (Brossart et al, 1993),
various studies differ in their interpretation with regard to stage
dependency and prognostic meaning of such a finding (Brossart
et al, 1993; Hoon et al, 1995; Kunter et al, 1996; Mellado et al, 1996;
Pitman et al, 1996). However, undoubtedly, tyrosinase, a rather
tissue specific enzyme, should be of principal use for detection of
melanoma cells also in other tissues but blood. In-situ hybridization
experiments in mice demonstrated that expression of the tyrosinase
gene is restricted to melanocytes in skin, hair follicles and uvea
(Beermann et al, 1992). In Northern blot analysis of mouse RNA,
tyrosinase transcription could be demonstrated in melanocytes and
to a lesser extent in normal testes, whereas brain, lung, heart,
kidneys, liver and muscles were negative (Muller et al, 1988).
At present, only a few papers address the use of tyrosinase
RT-PCR for detection of melanoma cells in surgically removed
lymph nodes (Wang et al, 1994; Van-der-Velde et al, 1996) or in
fine-needle aspirates derived from putative lymph node or in
transit metastases (Schwürzer-Voit et al, 1996). Studies to
evaluate this method in the context of routine clinical patient
management are urgently needed. Our study indicates that tyrosi-
nase RT-PCR could be of use in diagnosis of melanoma metas-
tases. In case of a positive RT-PCR, in our clinic definitive tumour
surgery is warranted directly, instead of open node biopsy. On the
other hand, in case of a negative RT-PCR from an ultrasonograph-
ically suspicious lesion, control by B-scan examination and FNA-
PCR in short intervals would allow to recognize a slow growing
metastasis still in time. Therefore, FNA-PCR together with B-scan
examination can properly fit into already published diagnostic
algorithms of unclear lesions (Basler et al, 1997), and may help to
make early diagnosis of metastatic disease less invasive and less
related to severe morbidity.
None of the lesions of control patients with inflammatory
disease or non-melanoma malignancy was positive when exam-
ined by FNA-PCR technique. Only one lymph node shown to be
non-specific in architecture by ultrasound B-scan was positive
by FNA-PCR without evidence of malignant disease now for
24+ months. Evaluating clinically and ultrasonographically suspi-
cious or unclear lesions, which subsequently were diagnosed as
melanoma metastases on histological grounds, the FNA-PCR
procedure was shown to exceed the sensitivity of the classic
FNAC method. This was particularly true for lesions smaller than
10 mm in diameter. However, with lesions larger than 10 mm of
diameter we were not able to show a significantly increased sensi-
tivity of FNA-PCR as compared to ultrasound B-scan (P < 0.07)
or FNAC (P = 0.5) alone.
One major point of criticism against RT-PCR of fine-needle
aspirates would be the argument of possible blood contamination
of aspirates, since circulating melanoma cells may influence the
result of the FNA-PCR. We therefore analysed blood samples,
obtained simultaneously with fine-needle aspirates, for the pres-
ence of tyrosinase transcripts. As shown in Table 5, the rate of
positive blood samples does not differ significantly for clinical
stages III or IV disease, regardless, whether they had a melanoma
metastasis or whether they were in a disease-free state at the time
of FNA-PCR. Furthermore, in only one patient who had a negative
blood test for tyrosinase, FNA-PCR of non-specific lymph nodes
in melanoma patients had negative results despite the fact that
17% of those patients exhibited positive blood samples.
CONCLUSION
We conclude that FNA-PCR examination of ultrasonographically
suspicious or unclear tumours might be of value in clinical
management of melanoma patients. In cases of large metastases
with diameters over 10 mm it facilitates the diagnosis if the exper-
tise of a well-trained cytologist is not available. However, for
the diagnosis of metastases with diameters less than 10 mm,
FNA-PCR proves to be highly sensitive and even superior to
FNAC. To determine its role in sentinel node staging should be
of great interest.
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